This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsNeptune Wellness Solutions (NTU) 주식 개요Operates as a consumer packaged goods company in Canada, the United States, and internationally. 자세히 보기NTU 펀더멘털 분석스노우플레이크 점수가치 평가2/6미래 성장0/6과거 실적0/6재무 건전성0/6배당0/6위험 분석지난 5년간 매년 수익이 13.6% 감소했습니다.의미 있는 시가총액이 없습니다(€106K)마이너스 주주 지분지난 1년 동안 주주가 크게 희석되었습니다.+ 위험 2건 추가모든 위험 점검 보기NTU Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.1198.2% 저평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-112m98m2016201920222025202620282031Revenue US$98.4mEarnings US$10.5mAdvancedSet Fair ValueView all narrativesNeptune Wellness Solutions Inc. 경쟁사NosiumSymbol: NGM:NOSIUM BMarket cap: SEK 10.6mBruush Oral CareSymbol: OTCPK:BRSH.FMarket cap: US$14.4kKoios BeverageSymbol: CNSX:FITMarket cap: CA$473.6kHillSymbol: TSXV:HILL.HMarket cap: CA$36.1k가격 이력 및 성과Neptune Wellness Solutions 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가US$0.1152주 최고가US$12.3252주 최저가US$0.04베타2.181개월 변동0%3개월 변동-10.66%1년 변동-97.90%3년 변동-99.99%5년 변동-100.00%IPO 이후 변동-100.00%최근 뉴스 및 업데이트공시 • Mar 09+ 1 more updateNeptune Wellness Solutions Inc. Appoints Michael De Geus as Interim President and Cedrick Billequey as Interim COONeptune Wellness Solutions Inc. announced the Company's Board of Directors has named Board member Michael De Geus Interim President, effective March 8, 2024. Mr. De Geus has served as an integral member of the previously disclosed Restructuring Committee of the Board of Directors following the furlough and departure of Michael Cammarata, who served as President and Chief Executive Officer since 2019. Additionally, the Company's Board of Directors has named Cedrick Billequey, currently General Manager of Neptune's subsidiary Biodroga Nutraceuticals Inc. ("Biodroga"), Interim Chief Operating Officer of Neptune. He will continue his role at Biodroga concurrently with his interim appointment. Mr. De Geus has been a director of Neptune since April 2020. He is a highly accomplished security executive with almost 20 years of domestic and international safety, protection and entrepreneurship experience. His 12-year career with the United States Secret Service afforded him the opportunity to become an expert in the art of protection and problem solving where he focused on safeguarding people, places and things all over the world. He is experienced in leading Presidential details for multiple US Presidents, leading cyber security, fraud, and financial crimes investigations, including the largest data breach cases in US Secret Service history, and operationalizing large mission-based teams. He is also the founder of Leatherback Gear (the only patented personal protection system D2C) and HERO Beverage Co. (with the goal of Helping Everyone Remain Operational, benefiting first responders, servicemen and women, and other heroes). He holds a Bachelor of Sciences in Criminal Justice from California State University, Fullerton, a Master of Sciences in International Relations from Troy State University, and was a PhD Candidate in Public Policy specializing in Homeland Security. Mr. Billequey has been leading Biodroga, Neptune's nutraceuticals brand subsidiary, for over three years, during which time Biodroga expanded its client portfolio and became a profitable company. He led the restructuring of the entire Biodroga team and its processes to ensure superior customer service levels and scalability. Cedrick possesses significant experience and knowledge in B2B business development and supply chain optimization, with a solid background in finance. Prior to joining Biodroga, Cedrick worked over 20 years in the Pharmaceutical industry where he held various leadership roles in International Business Development, Supply Chain, Project Management and Finance. He worked many years at Pharmascience, one of the largest generic pharmaceutical companies in Canada, before joining Jamp Pharma Corporation as Vice-President International Business Development, one of the fastest growing Canadian Pharmaceutical companies. In 1999, he received a Bachelor of Business Administration in Finance from the University of Alabama in Huntsville.공시 • Mar 07+ 1 more updateNeptune Wellness Solutions Inc.(OTCPK:NEPT.F) dropped from NASDAQ Composite IndexNeptune Wellness Solutions Inc removed공시 • Feb 17Neptune Wellness Solutions Inc. to Report Q3, 2024 Results on Feb 16, 2024Neptune Wellness Solutions Inc. announced that they will report Q3, 2024 results on Feb 16, 2024공시 • Feb 16Neptune Wellness Solutions Inc. announced delayed 10-Q filingOn 02/15/2024, Neptune Wellness Solutions Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Dec 05Neptune Wellness Announces Receipt of Nasdaq Delisting Notice and Intention to AppealNeptune Wellness Solutions Inc. (‘Neptune’ or the ‘Company’) announced that it received notification from the Nasdaq Stock Market LLC (‘Nasdaq’) on November 30, 2023, that Nasdaq has determined to delist the Company's common shares (the ‘Common Shares’) due to noncompliance with the Minimum Bid Requirement and the Stockholders’ Equity Requirement (each as defined below). The notification specifies that the Company is not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market (NASDAQ Listing Rule 5550(a)(2)), as the bid price for the Common Shares on Nasdaq closed below USD 1.00 (the ‘Minimum Bid Requirement’) for 30 consecutive trading days. As the Company previously implemented two reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one, it is not eligible for any compliance period specified in Rule 5810(c)(3)(A). In addition, as previously disclosed, the Company received notification on July 19, 2023, that it was not in compliance with the minimum stockholders’ equity requirement (NASDAQ Listing Rule 5550(b)(1)), as the Company's stockholders’ equity was below the minimum USD 2.5 million required (the ‘Stockholders’ Equity Requirement’). The Company was provided 180 calendar days, or until January 16, 2024, to regain compliance with the Stockholders’ Equity Requirement. This deficiency serves as an additional and separate basis for delisting. The Company intends to appeal the determination made by Nasdaq within seven calendar days, or by December 7, 2023, pursuant to the procedures set forth in the Nasdaq Listing Rules. The Nasdaq Listing Rules provide that the Company may request a hearing before a Nasdaq Hearings Panel (the ‘Panel’), and such hearing request will stay the suspension of the Company's securities pending the Panel's decision. There can be no assurance as to the success or outcome of the appeal.공시 • Nov 21Neptune Wellness Solutions Inc. (NasdaqCM:NEPT) entered into a non-binding Letter of Intent to acquire Datasys Group Inc. approximately $110 million.Neptune Wellness Solutions Inc. (NasdaqCM:NEPT) entered into a non-binding Letter of Intent to acquire Datasys Group Inc. for approximately $110 million on November 20, 2023. Total potential consideration for the acquisition is $112 million in a combination of $20 million in cash at closing, $32 million in restricted equity based on a pre-closing VWAP of the Company’s share price on NASDAQ (subject to a minimum of 10 million shares) and restricted until three gradual releases over 10-30 months, a 5-year $31 million PIK seller note. An earnout payment ranging from $5 million to $22 million, subject to Datasys achieving 2024 EBITDA thresholds between $13 million and $16 million. The Proposed Transaction is subject to the negotiation of definitive documentation between the parties and it is anticipated that closing of the Proposed Transaction would be subject to shareholder approval and additional terms and conditions, including the need for the Company to secure financing for the cash portion of the consideration and satisfactory due diligence by the respective parties. There can be no assurance that a definitive agreement will be entered into or that the Proposed Transaction will be consummated on the terms or timeframe currently contemplated, or at all.더 많은 업데이트 보기Recent updates공시 • Mar 09+ 1 more updateNeptune Wellness Solutions Inc. Appoints Michael De Geus as Interim President and Cedrick Billequey as Interim COONeptune Wellness Solutions Inc. announced the Company's Board of Directors has named Board member Michael De Geus Interim President, effective March 8, 2024. Mr. De Geus has served as an integral member of the previously disclosed Restructuring Committee of the Board of Directors following the furlough and departure of Michael Cammarata, who served as President and Chief Executive Officer since 2019. Additionally, the Company's Board of Directors has named Cedrick Billequey, currently General Manager of Neptune's subsidiary Biodroga Nutraceuticals Inc. ("Biodroga"), Interim Chief Operating Officer of Neptune. He will continue his role at Biodroga concurrently with his interim appointment. Mr. De Geus has been a director of Neptune since April 2020. He is a highly accomplished security executive with almost 20 years of domestic and international safety, protection and entrepreneurship experience. His 12-year career with the United States Secret Service afforded him the opportunity to become an expert in the art of protection and problem solving where he focused on safeguarding people, places and things all over the world. He is experienced in leading Presidential details for multiple US Presidents, leading cyber security, fraud, and financial crimes investigations, including the largest data breach cases in US Secret Service history, and operationalizing large mission-based teams. He is also the founder of Leatherback Gear (the only patented personal protection system D2C) and HERO Beverage Co. (with the goal of Helping Everyone Remain Operational, benefiting first responders, servicemen and women, and other heroes). He holds a Bachelor of Sciences in Criminal Justice from California State University, Fullerton, a Master of Sciences in International Relations from Troy State University, and was a PhD Candidate in Public Policy specializing in Homeland Security. Mr. Billequey has been leading Biodroga, Neptune's nutraceuticals brand subsidiary, for over three years, during which time Biodroga expanded its client portfolio and became a profitable company. He led the restructuring of the entire Biodroga team and its processes to ensure superior customer service levels and scalability. Cedrick possesses significant experience and knowledge in B2B business development and supply chain optimization, with a solid background in finance. Prior to joining Biodroga, Cedrick worked over 20 years in the Pharmaceutical industry where he held various leadership roles in International Business Development, Supply Chain, Project Management and Finance. He worked many years at Pharmascience, one of the largest generic pharmaceutical companies in Canada, before joining Jamp Pharma Corporation as Vice-President International Business Development, one of the fastest growing Canadian Pharmaceutical companies. In 1999, he received a Bachelor of Business Administration in Finance from the University of Alabama in Huntsville.공시 • Mar 07+ 1 more updateNeptune Wellness Solutions Inc.(OTCPK:NEPT.F) dropped from NASDAQ Composite IndexNeptune Wellness Solutions Inc removed공시 • Feb 17Neptune Wellness Solutions Inc. to Report Q3, 2024 Results on Feb 16, 2024Neptune Wellness Solutions Inc. announced that they will report Q3, 2024 results on Feb 16, 2024공시 • Feb 16Neptune Wellness Solutions Inc. announced delayed 10-Q filingOn 02/15/2024, Neptune Wellness Solutions Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Dec 05Neptune Wellness Announces Receipt of Nasdaq Delisting Notice and Intention to AppealNeptune Wellness Solutions Inc. (‘Neptune’ or the ‘Company’) announced that it received notification from the Nasdaq Stock Market LLC (‘Nasdaq’) on November 30, 2023, that Nasdaq has determined to delist the Company's common shares (the ‘Common Shares’) due to noncompliance with the Minimum Bid Requirement and the Stockholders’ Equity Requirement (each as defined below). The notification specifies that the Company is not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market (NASDAQ Listing Rule 5550(a)(2)), as the bid price for the Common Shares on Nasdaq closed below USD 1.00 (the ‘Minimum Bid Requirement’) for 30 consecutive trading days. As the Company previously implemented two reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one, it is not eligible for any compliance period specified in Rule 5810(c)(3)(A). In addition, as previously disclosed, the Company received notification on July 19, 2023, that it was not in compliance with the minimum stockholders’ equity requirement (NASDAQ Listing Rule 5550(b)(1)), as the Company's stockholders’ equity was below the minimum USD 2.5 million required (the ‘Stockholders’ Equity Requirement’). The Company was provided 180 calendar days, or until January 16, 2024, to regain compliance with the Stockholders’ Equity Requirement. This deficiency serves as an additional and separate basis for delisting. The Company intends to appeal the determination made by Nasdaq within seven calendar days, or by December 7, 2023, pursuant to the procedures set forth in the Nasdaq Listing Rules. The Nasdaq Listing Rules provide that the Company may request a hearing before a Nasdaq Hearings Panel (the ‘Panel’), and such hearing request will stay the suspension of the Company's securities pending the Panel's decision. There can be no assurance as to the success or outcome of the appeal.공시 • Nov 21Neptune Wellness Solutions Inc. (NasdaqCM:NEPT) entered into a non-binding Letter of Intent to acquire Datasys Group Inc. approximately $110 million.Neptune Wellness Solutions Inc. (NasdaqCM:NEPT) entered into a non-binding Letter of Intent to acquire Datasys Group Inc. for approximately $110 million on November 20, 2023. Total potential consideration for the acquisition is $112 million in a combination of $20 million in cash at closing, $32 million in restricted equity based on a pre-closing VWAP of the Company’s share price on NASDAQ (subject to a minimum of 10 million shares) and restricted until three gradual releases over 10-30 months, a 5-year $31 million PIK seller note. An earnout payment ranging from $5 million to $22 million, subject to Datasys achieving 2024 EBITDA thresholds between $13 million and $16 million. The Proposed Transaction is subject to the negotiation of definitive documentation between the parties and it is anticipated that closing of the Proposed Transaction would be subject to shareholder approval and additional terms and conditions, including the need for the Company to secure financing for the cash portion of the consideration and satisfactory due diligence by the respective parties. There can be no assurance that a definitive agreement will be entered into or that the Proposed Transaction will be consummated on the terms or timeframe currently contemplated, or at all.공시 • Oct 14Neptune Wellness Solutions Inc. Announces Completed Settlement of Class Action LawsuitNeptune Wellness Solutions Inc. has completed the previously announced settlement of a putative shareholder class action lawsuit filed against Neptune and certain of its current and former officers and directors.공시 • Aug 17Neptune Wellness Solutions Inc. announced delayed 10-Q filingOn 08/15/2023, Neptune Wellness Solutions Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Aug 05Neptune Wellness Solutions Inc. Announces CFO ChangesNeptune Wellness Solutions Inc. announced the promotion of Lisa Gainsborg, currently Neptune's Financial Controller, to Interim Chief Financial Officer, effective immediately, replacing Raymond Silcock who has resigned for personal reasons. Ms. Gainsborg possesses significant experience and knowledge of accounting and finance across both public and private companies, with background in financial statement preparation, Securities and Exchange Commission reporting, Sarbanes-Oxley compliance, the creation of accounting and reporting controls and procedures, and experience with developing enterprise resource planning systems. Ms. Gainsborg previously held financial leadership roles at several companies including Basanite Inc., Zero Gravity Solutions Inc., A+ Accounting Services Inc. She has also provided chief financial officer consulting services and accounting system support for clients and prepared corporate, partnership, and individual tax returns. Ms. Gainsborg is a Certified Public Accountant in Florida and Maryland. She received a Bachelor of Business Administration in Accounting from Hofstra University in 1989.공시 • Jul 01Neptune Wellness Solutions Inc. announced delayed annual 10-K filingOn 06/30/2023, Neptune Wellness Solutions Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • May 17Neptune Wellness Solutions Inc. has completed a Follow-on Equity Offering in the amount of $4 million.Neptune Wellness Solutions Inc. has completed a Follow-on Equity Offering in the amount of $4 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 12,121,212 Price\Range: $0.33 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 12,121,212공시 • Feb 16Neptune Wellness Solutions Inc. announced delayed 10-Q filingOn 02/15/2023, Neptune Wellness Solutions Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Jan 07Neptune Wellness Solutions Announces Receipt of NASDAQ NotificationNeptune Wellness Solutions Inc. announced that the Company has received a written notification (the "Notification Letter") from the Nasdaq Stock Market LLC ("Nasdaq") on December 29, 2022, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), which requires that the closing bid price for the Company's common shares listed on Nasdaq be maintained at a minimum of $1.00. Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's common shares for the 30 consecutive business days from November 15, 2022 to December 28, 2022, the Company no longer met the minimum bid price requirement. The Notification Letter has no immediate effect on the listing of the Company's common shares on Nasdaq. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until June 27, 2023, to regain compliance with the minimum bid price requirement, during which time the Company's common shares will continue to trade on the Nasdaq Capital Market. To regain compliance, the Company's common shares must have a closing bid price of at least $1.00 for a minimum of 10 consecutive trading days. In the event the Company does not regain compliance by June 27, 2023, the Company may be eligible for additional time to regain compliance or may face delisting. The Company's business operations are not affected by the receipt of the Notification Letter. The Company intends to monitor the closing bid price of its common shares and may, if appropriate, consider implementing available options, including, but not limited to, implementing a reverse share split of its outstanding common shares, to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules.공시 • Nov 23Neptune Wellness Solutions Inc. Revises Revenue Guidance for the Second Quarter of Fiscal Year 2023Neptune Wellness Solutions Inc. revised revenue guidance for the second quarter of fiscal year 2023. For the period, the company expects revenue range from USD 12.5 million to USD 13.5 million to USD 11.5 million to USD 12.5 million. Approximately 70% of second quarter revenues were from Sprout, representing a double digit increase compared to the same quarter last year.공시 • Nov 16+ 1 more updateNeptune Wellness Solutions Inc. announced delayed 10-Q filingOn 11/15/2022, Neptune Wellness Solutions Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Nov 10PurCann Pharma Inc. completed the acquisition of Cannabis Assets of Neptune Wellness Solutions Inc. for CAD 5.2 million.PurCann Pharma Inc. entered into a binding agreement to acquire Cannabis Assets of Neptune Wellness Solutions Inc. for approximately CAD 6 million on October 16, 2022. The cannabis assets include includes the cannabis plant in Sherbrooke, Québec, the Mood Ring and PanHash brands, and related assets. Neptune intends to use the net proceeds from the sale of these assets to for working capital and other general corporate purposes. The Transaction is expected to close on or before November 15, 2022. Stifel Nicolaus Canada Inc. acted as financial opinion provider and exclusive financial advisor to Neptune Wellness Solutions Inc. Osler, Hoskin & Harcourt LLP acted as legal advisor to Neptune Wellness Solutions Inc. PurCann Pharma Inc. completed the acquisition of Cannabis Assets of Neptune Wellness Solutions Inc. for CAD 5.2 million on November 9, 2022.공시 • Oct 22Neptune Wellness Solutions Inc. Reaches Settlement in Shareholder Class Action LitigationNeptune Wellness Solutions Inc. announced that it has agreed to settle and resolve a putative shareholder class action lawsuit filed against Neptune and certain of its current and former officers and directors, captioned Gong v. Neptune Wellness Solutions Inc. (Case No. 2:21-cv-01386-ENV-ARL) pending in the United States District Court for the Eastern District of New York (the "Court"). The litigation relates to allegations that, among other things, the Company had made misrepresentations of material information. The settlement provides for a gross payment to the class of between $4 and $4.25 million, with the exact amount being within the Company's control and dependent on the type of consideration used. The settlement is subject to Court approval and certification by the Court of the class. The settlement will resolve this matter against all defendants, and the consideration will be used to satisfy settlement administrator expenses, plaintiffs' attorneys' fees and costs, and payments to all members of the Class. In exchange for the settlement consideration, the Company and the other defendants will be released from all claims by the plaintiffs and the class. The Company denies all wrongdoing and liability and the settlement does not constitute an admission of wrongdoing or liability by the Company or any defendant. The class is comprised of all persons and entities that purchased or otherwise acquired Neptune securities on the NASDAQ or another U.S. trading venue between July 24, 2019, and July 15, 2021. The settlement is contingent upon various conditions, including, but not limited to, preliminary approval by the Court and final approval by the Court after notice to the class, certification of the class and a hearing. There can be no assurance that the settlement will be approved by the Court nor upheld if challenged on appeal. In addition, the Company has the right to terminate the settlement agreement under certain conditions. The Company has filed a claim for coverage with its insurance carrier, which was subsequently denied. The Company is contesting the denial of coverage.공시 • Oct 19PurCann Pharma Inc. entered into a binding agreement to acquire Cannabis Assets of Neptune Wellness Solutions Inc. for approximately CAD 6 million.PurCann Pharma Inc. entered into a binding agreement to acquire Cannabis Assets of Neptune Wellness Solutions Inc. for approximately CAD 6 million on October 16, 2022. The cannabis assets include includes the cannabis plant in Sherbrooke, Québec, the Mood Ring and PanHash brands, and related assets. Neptune intends to use the net proceeds from the sale of these assets to for working capital and other general corporate purposes. The Transaction is expected to close on or before November 15, 2022. Stifel Nicolaus Canada Inc. acted as financial opinion provider and exclusive financial advisor to Neptune Wellness Solutions Inc. Osler, Hoskin & Harcourt LLP acted as legal advisor to Neptune Wellness Solutions Inc.공시 • Oct 13Neptune Wellness Solutions Inc. has completed a Follow-on Equity Offering in the amount of $6.000002 million.Neptune Wellness Solutions Inc. has completed a Follow-on Equity Offering in the amount of $6.000002 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 3,208,557 Price\Range: $1.87 Discount Per Security: $0.0748 Transaction Features: Registered Direct Offering공시 • Oct 12+ 1 more updateNeptune Wellness Solutions Inc. has completed a Follow-on Equity Offering in the amount of $6.000002 million.Neptune Wellness Solutions Inc. has completed a Follow-on Equity Offering in the amount of $6.000002 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 3,208,557 Price\Range: $1.87 Discount Per Security: $0.0748 Transaction Features: Registered Direct OfferingBoard Change • Jun 02High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. 6 highly experienced directors. Independent Director Ronald Denis is the most experienced director on the board, commencing their role in 2000. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Recent Insider Transactions • Mar 03President recently bought €346k worth of stockOn the 1st of March, Michael Cammarata bought around 1m shares on-market at roughly €0.31 per share. This was the largest purchase by an insider in the last 3 months. Michael has been a buyer over the last 12 months, purchasing a net total of €365k worth in shares.Reported Earnings • Feb 11Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2022 results: CA$0.11 loss per share (up from CA$0.59 loss in 3Q 2021). Revenue: CA$18.4m (up 456% from 3Q 2021). Net loss: CA$18.7m (loss narrowed 75% from 3Q 2021). Revenue exceeded analyst estimates by 6.1%. Over the next year, revenue is forecast to grow 81%, compared to a 6.9% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has fallen by 57% per year, which means it is performing significantly worse than earnings.Reported Earnings • Nov 16Second quarter 2022 earnings released: CA$0.076 loss per share (vs CA$0.20 loss in 2Q 2021)The company reported a soft second quarter result with weaker revenues and control over costs, although losses reduced. Second quarter 2022 results: Revenue: CA$15.7m (down 45% from 2Q 2021). Net loss: CA$12.7m (loss narrowed 42% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 47% per year, which means it has not declined as severely as earnings.Board Change • Sep 13High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Jane Pemberton was the last director to join the board, commencing their role in 2020. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Board Change • Sep 05High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Jane Pemberton was the last director to join the board, commencing their role in 2020. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Executive Departure • Sep 01Independent Director Jane Pemberton has left the companyOn the 26th of August, Jane Pemberton's tenure as Independent Director ended after 1.0 years in the role. As of June 2021, Jane still personally held only 9.67k shares (€9.2k worth at the time). A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 1.25 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Sep 01Independent Director Frank Rochon has left the companyOn the 26th of August, Frank Rochon's tenure as Independent Director ended after 1.0 years in the role. As of June 2021, Frank still personally held only 4.77k shares (€4.6k worth at the time). A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 1.25 years, which is considered inexperienced in the Simply Wall St Risk Model.Recent Insider Transactions • Jul 22Independent Chairman recently bought €67k worth of stockOn the 20th of July, John Moretz bought around 100k shares on-market at roughly €0.67 per share. This was the largest purchase by an insider in the last 3 months. John has been a buyer over the last 12 months, purchasing a net total of €210k worth in shares.Reported Earnings • Jul 18Full year 2021 earnings released: CA$1.38 loss per share (vs CA$0.68 loss in FY 2020)The company reported a mediocre full year result with increased losses and weaker control over costs, although revenues improved. Full year 2021 results: Revenue: CA$46.8m (up 58% from FY 2020). Net loss: CA$167.1m (loss widened 175% from FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 58 percentage points per year, which is a significant difference in performance.Executive Departure • May 23Independent Director has left the companyOn the 17th of May, Richard Schottenfeld's tenure as Independent Director ended after 4.9 years in the role. As of March 2021, Richard personally held 180.45k shares (€182k worth at the time). A total of 3 executives have left over the last 12 months.Is New 90 Day High Low • Mar 06New 90-day low: €1.15The company is down 18% from its price of €1.40 on 04 December 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is down 4.0% over the same period.Reported Earnings • Feb 18Third quarter 2021 earnings released: CA$0.59 loss per share (vs CA$0.06 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: CA$3.32m (down 64% from 3Q 2020). Net loss: CA$73.8m (down CA$79.4m from profit in 3Q 2020).Analyst Estimate Surprise Post Earnings • Feb 18Revenue misses expectationsRevenue missed analyst estimates by 78%. Over the next year, revenue is forecast to grow 183%, compared to a 5.4% growth forecast for the Personal Products industry in Germany.Is New 90 Day High Low • Feb 06New 90-day high: €1.93The company is up 5.0% from its price of €1.83 on 06 November 2020. The German market is up 15% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Personal Products industry, which is down 5.0% over the same period.Is New 90 Day High Low • Dec 15New 90-day low: €1.17The company is down 41% from its price of €1.97 on 16 September 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Recent Insider Transactions • Nov 22Independent Chairman recently bought €143k worth of stockOn the 19th of November, John Moretz bought around 100k shares on-market at roughly €1.43 per share. This was the largest purchase by an insider in the last 3 months. John has been a buyer over the last 12 months, purchasing a net total of €469k worth in shares.주주 수익률NTUDE Personal ProductsDE 시장7D0%-1.7%0.6%1Y-97.9%-5.2%3.8%전체 주주 수익률 보기수익률 대 산업: NTU은 지난 1년 동안 -5.2%의 수익을 기록한 German Personal Products 산업보다 저조한 성과를 냈습니다.수익률 대 시장: NTU은 지난 1년 동안 3.8%를 기록한 German 시장보다 저조한 성과를 냈습니다.주가 변동성Is NTU's price volatile compared to industry and market?NTU volatilityNTU Average Weekly Movementn/aPersonal Products Industry Average Movement5.2%Market Average Movement5.8%10% most volatile stocks in DE Market13.3%10% least volatile stocks in DE Market2.8%안정적인 주가: NTU의 주가는 지난 3개월 동안 German 시장보다 변동성이 컸습니다.시간에 따른 변동성: Insufficient data to determine NTU의 변동성 변화를 판단할 수 없습니다.회사 소개설립직원 수CEO웹사이트199850Mike de Geuswww.neptunecorp.com더 보기Neptune Wellness Solutions Inc. 기초 지표 요약Neptune Wellness Solutions의 순이익과 매출은 시가총액과 어떻게 비교됩니까?NTU 기초 통계시가총액€105.51k순이익 (TTM)-€49.84m매출 (TTM)€36.43m0.0x주가매출비율(P/S)0.0x주가수익비율(P/E)NTU는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표NTU 손익계산서 (TTM)매출US$39.11m매출원가US$39.87m총이익-US$758.79k기타 비용US$52.76m순이익-US$53.52m최근 보고된 실적Dec 31, 2023다음 실적 발표일해당 없음주당순이익(EPS)-10.86총이익률-1.94%순이익률-136.83%부채/자본 비율-49.8%NTU의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/06/12 17:05종가2024/03/15 00:00수익2023/12/31연간 수익2023/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Neptune Wellness Solutions Inc.는 10명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Aaron GreyAlliance Global PartnersDouglas LoeCantor Fitzgerald Canada CorporationJason ButlerCitizens JMP Securities, LLC7명의 분석가 더 보기
공시 • Mar 09+ 1 more updateNeptune Wellness Solutions Inc. Appoints Michael De Geus as Interim President and Cedrick Billequey as Interim COONeptune Wellness Solutions Inc. announced the Company's Board of Directors has named Board member Michael De Geus Interim President, effective March 8, 2024. Mr. De Geus has served as an integral member of the previously disclosed Restructuring Committee of the Board of Directors following the furlough and departure of Michael Cammarata, who served as President and Chief Executive Officer since 2019. Additionally, the Company's Board of Directors has named Cedrick Billequey, currently General Manager of Neptune's subsidiary Biodroga Nutraceuticals Inc. ("Biodroga"), Interim Chief Operating Officer of Neptune. He will continue his role at Biodroga concurrently with his interim appointment. Mr. De Geus has been a director of Neptune since April 2020. He is a highly accomplished security executive with almost 20 years of domestic and international safety, protection and entrepreneurship experience. His 12-year career with the United States Secret Service afforded him the opportunity to become an expert in the art of protection and problem solving where he focused on safeguarding people, places and things all over the world. He is experienced in leading Presidential details for multiple US Presidents, leading cyber security, fraud, and financial crimes investigations, including the largest data breach cases in US Secret Service history, and operationalizing large mission-based teams. He is also the founder of Leatherback Gear (the only patented personal protection system D2C) and HERO Beverage Co. (with the goal of Helping Everyone Remain Operational, benefiting first responders, servicemen and women, and other heroes). He holds a Bachelor of Sciences in Criminal Justice from California State University, Fullerton, a Master of Sciences in International Relations from Troy State University, and was a PhD Candidate in Public Policy specializing in Homeland Security. Mr. Billequey has been leading Biodroga, Neptune's nutraceuticals brand subsidiary, for over three years, during which time Biodroga expanded its client portfolio and became a profitable company. He led the restructuring of the entire Biodroga team and its processes to ensure superior customer service levels and scalability. Cedrick possesses significant experience and knowledge in B2B business development and supply chain optimization, with a solid background in finance. Prior to joining Biodroga, Cedrick worked over 20 years in the Pharmaceutical industry where he held various leadership roles in International Business Development, Supply Chain, Project Management and Finance. He worked many years at Pharmascience, one of the largest generic pharmaceutical companies in Canada, before joining Jamp Pharma Corporation as Vice-President International Business Development, one of the fastest growing Canadian Pharmaceutical companies. In 1999, he received a Bachelor of Business Administration in Finance from the University of Alabama in Huntsville.
공시 • Mar 07+ 1 more updateNeptune Wellness Solutions Inc.(OTCPK:NEPT.F) dropped from NASDAQ Composite IndexNeptune Wellness Solutions Inc removed
공시 • Feb 17Neptune Wellness Solutions Inc. to Report Q3, 2024 Results on Feb 16, 2024Neptune Wellness Solutions Inc. announced that they will report Q3, 2024 results on Feb 16, 2024
공시 • Feb 16Neptune Wellness Solutions Inc. announced delayed 10-Q filingOn 02/15/2024, Neptune Wellness Solutions Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Dec 05Neptune Wellness Announces Receipt of Nasdaq Delisting Notice and Intention to AppealNeptune Wellness Solutions Inc. (‘Neptune’ or the ‘Company’) announced that it received notification from the Nasdaq Stock Market LLC (‘Nasdaq’) on November 30, 2023, that Nasdaq has determined to delist the Company's common shares (the ‘Common Shares’) due to noncompliance with the Minimum Bid Requirement and the Stockholders’ Equity Requirement (each as defined below). The notification specifies that the Company is not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market (NASDAQ Listing Rule 5550(a)(2)), as the bid price for the Common Shares on Nasdaq closed below USD 1.00 (the ‘Minimum Bid Requirement’) for 30 consecutive trading days. As the Company previously implemented two reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one, it is not eligible for any compliance period specified in Rule 5810(c)(3)(A). In addition, as previously disclosed, the Company received notification on July 19, 2023, that it was not in compliance with the minimum stockholders’ equity requirement (NASDAQ Listing Rule 5550(b)(1)), as the Company's stockholders’ equity was below the minimum USD 2.5 million required (the ‘Stockholders’ Equity Requirement’). The Company was provided 180 calendar days, or until January 16, 2024, to regain compliance with the Stockholders’ Equity Requirement. This deficiency serves as an additional and separate basis for delisting. The Company intends to appeal the determination made by Nasdaq within seven calendar days, or by December 7, 2023, pursuant to the procedures set forth in the Nasdaq Listing Rules. The Nasdaq Listing Rules provide that the Company may request a hearing before a Nasdaq Hearings Panel (the ‘Panel’), and such hearing request will stay the suspension of the Company's securities pending the Panel's decision. There can be no assurance as to the success or outcome of the appeal.
공시 • Nov 21Neptune Wellness Solutions Inc. (NasdaqCM:NEPT) entered into a non-binding Letter of Intent to acquire Datasys Group Inc. approximately $110 million.Neptune Wellness Solutions Inc. (NasdaqCM:NEPT) entered into a non-binding Letter of Intent to acquire Datasys Group Inc. for approximately $110 million on November 20, 2023. Total potential consideration for the acquisition is $112 million in a combination of $20 million in cash at closing, $32 million in restricted equity based on a pre-closing VWAP of the Company’s share price on NASDAQ (subject to a minimum of 10 million shares) and restricted until three gradual releases over 10-30 months, a 5-year $31 million PIK seller note. An earnout payment ranging from $5 million to $22 million, subject to Datasys achieving 2024 EBITDA thresholds between $13 million and $16 million. The Proposed Transaction is subject to the negotiation of definitive documentation between the parties and it is anticipated that closing of the Proposed Transaction would be subject to shareholder approval and additional terms and conditions, including the need for the Company to secure financing for the cash portion of the consideration and satisfactory due diligence by the respective parties. There can be no assurance that a definitive agreement will be entered into or that the Proposed Transaction will be consummated on the terms or timeframe currently contemplated, or at all.
공시 • Mar 09+ 1 more updateNeptune Wellness Solutions Inc. Appoints Michael De Geus as Interim President and Cedrick Billequey as Interim COONeptune Wellness Solutions Inc. announced the Company's Board of Directors has named Board member Michael De Geus Interim President, effective March 8, 2024. Mr. De Geus has served as an integral member of the previously disclosed Restructuring Committee of the Board of Directors following the furlough and departure of Michael Cammarata, who served as President and Chief Executive Officer since 2019. Additionally, the Company's Board of Directors has named Cedrick Billequey, currently General Manager of Neptune's subsidiary Biodroga Nutraceuticals Inc. ("Biodroga"), Interim Chief Operating Officer of Neptune. He will continue his role at Biodroga concurrently with his interim appointment. Mr. De Geus has been a director of Neptune since April 2020. He is a highly accomplished security executive with almost 20 years of domestic and international safety, protection and entrepreneurship experience. His 12-year career with the United States Secret Service afforded him the opportunity to become an expert in the art of protection and problem solving where he focused on safeguarding people, places and things all over the world. He is experienced in leading Presidential details for multiple US Presidents, leading cyber security, fraud, and financial crimes investigations, including the largest data breach cases in US Secret Service history, and operationalizing large mission-based teams. He is also the founder of Leatherback Gear (the only patented personal protection system D2C) and HERO Beverage Co. (with the goal of Helping Everyone Remain Operational, benefiting first responders, servicemen and women, and other heroes). He holds a Bachelor of Sciences in Criminal Justice from California State University, Fullerton, a Master of Sciences in International Relations from Troy State University, and was a PhD Candidate in Public Policy specializing in Homeland Security. Mr. Billequey has been leading Biodroga, Neptune's nutraceuticals brand subsidiary, for over three years, during which time Biodroga expanded its client portfolio and became a profitable company. He led the restructuring of the entire Biodroga team and its processes to ensure superior customer service levels and scalability. Cedrick possesses significant experience and knowledge in B2B business development and supply chain optimization, with a solid background in finance. Prior to joining Biodroga, Cedrick worked over 20 years in the Pharmaceutical industry where he held various leadership roles in International Business Development, Supply Chain, Project Management and Finance. He worked many years at Pharmascience, one of the largest generic pharmaceutical companies in Canada, before joining Jamp Pharma Corporation as Vice-President International Business Development, one of the fastest growing Canadian Pharmaceutical companies. In 1999, he received a Bachelor of Business Administration in Finance from the University of Alabama in Huntsville.
공시 • Mar 07+ 1 more updateNeptune Wellness Solutions Inc.(OTCPK:NEPT.F) dropped from NASDAQ Composite IndexNeptune Wellness Solutions Inc removed
공시 • Feb 17Neptune Wellness Solutions Inc. to Report Q3, 2024 Results on Feb 16, 2024Neptune Wellness Solutions Inc. announced that they will report Q3, 2024 results on Feb 16, 2024
공시 • Feb 16Neptune Wellness Solutions Inc. announced delayed 10-Q filingOn 02/15/2024, Neptune Wellness Solutions Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Dec 05Neptune Wellness Announces Receipt of Nasdaq Delisting Notice and Intention to AppealNeptune Wellness Solutions Inc. (‘Neptune’ or the ‘Company’) announced that it received notification from the Nasdaq Stock Market LLC (‘Nasdaq’) on November 30, 2023, that Nasdaq has determined to delist the Company's common shares (the ‘Common Shares’) due to noncompliance with the Minimum Bid Requirement and the Stockholders’ Equity Requirement (each as defined below). The notification specifies that the Company is not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market (NASDAQ Listing Rule 5550(a)(2)), as the bid price for the Common Shares on Nasdaq closed below USD 1.00 (the ‘Minimum Bid Requirement’) for 30 consecutive trading days. As the Company previously implemented two reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one, it is not eligible for any compliance period specified in Rule 5810(c)(3)(A). In addition, as previously disclosed, the Company received notification on July 19, 2023, that it was not in compliance with the minimum stockholders’ equity requirement (NASDAQ Listing Rule 5550(b)(1)), as the Company's stockholders’ equity was below the minimum USD 2.5 million required (the ‘Stockholders’ Equity Requirement’). The Company was provided 180 calendar days, or until January 16, 2024, to regain compliance with the Stockholders’ Equity Requirement. This deficiency serves as an additional and separate basis for delisting. The Company intends to appeal the determination made by Nasdaq within seven calendar days, or by December 7, 2023, pursuant to the procedures set forth in the Nasdaq Listing Rules. The Nasdaq Listing Rules provide that the Company may request a hearing before a Nasdaq Hearings Panel (the ‘Panel’), and such hearing request will stay the suspension of the Company's securities pending the Panel's decision. There can be no assurance as to the success or outcome of the appeal.
공시 • Nov 21Neptune Wellness Solutions Inc. (NasdaqCM:NEPT) entered into a non-binding Letter of Intent to acquire Datasys Group Inc. approximately $110 million.Neptune Wellness Solutions Inc. (NasdaqCM:NEPT) entered into a non-binding Letter of Intent to acquire Datasys Group Inc. for approximately $110 million on November 20, 2023. Total potential consideration for the acquisition is $112 million in a combination of $20 million in cash at closing, $32 million in restricted equity based on a pre-closing VWAP of the Company’s share price on NASDAQ (subject to a minimum of 10 million shares) and restricted until three gradual releases over 10-30 months, a 5-year $31 million PIK seller note. An earnout payment ranging from $5 million to $22 million, subject to Datasys achieving 2024 EBITDA thresholds between $13 million and $16 million. The Proposed Transaction is subject to the negotiation of definitive documentation between the parties and it is anticipated that closing of the Proposed Transaction would be subject to shareholder approval and additional terms and conditions, including the need for the Company to secure financing for the cash portion of the consideration and satisfactory due diligence by the respective parties. There can be no assurance that a definitive agreement will be entered into or that the Proposed Transaction will be consummated on the terms or timeframe currently contemplated, or at all.
공시 • Oct 14Neptune Wellness Solutions Inc. Announces Completed Settlement of Class Action LawsuitNeptune Wellness Solutions Inc. has completed the previously announced settlement of a putative shareholder class action lawsuit filed against Neptune and certain of its current and former officers and directors.
공시 • Aug 17Neptune Wellness Solutions Inc. announced delayed 10-Q filingOn 08/15/2023, Neptune Wellness Solutions Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Aug 05Neptune Wellness Solutions Inc. Announces CFO ChangesNeptune Wellness Solutions Inc. announced the promotion of Lisa Gainsborg, currently Neptune's Financial Controller, to Interim Chief Financial Officer, effective immediately, replacing Raymond Silcock who has resigned for personal reasons. Ms. Gainsborg possesses significant experience and knowledge of accounting and finance across both public and private companies, with background in financial statement preparation, Securities and Exchange Commission reporting, Sarbanes-Oxley compliance, the creation of accounting and reporting controls and procedures, and experience with developing enterprise resource planning systems. Ms. Gainsborg previously held financial leadership roles at several companies including Basanite Inc., Zero Gravity Solutions Inc., A+ Accounting Services Inc. She has also provided chief financial officer consulting services and accounting system support for clients and prepared corporate, partnership, and individual tax returns. Ms. Gainsborg is a Certified Public Accountant in Florida and Maryland. She received a Bachelor of Business Administration in Accounting from Hofstra University in 1989.
공시 • Jul 01Neptune Wellness Solutions Inc. announced delayed annual 10-K filingOn 06/30/2023, Neptune Wellness Solutions Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • May 17Neptune Wellness Solutions Inc. has completed a Follow-on Equity Offering in the amount of $4 million.Neptune Wellness Solutions Inc. has completed a Follow-on Equity Offering in the amount of $4 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 12,121,212 Price\Range: $0.33 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 12,121,212
공시 • Feb 16Neptune Wellness Solutions Inc. announced delayed 10-Q filingOn 02/15/2023, Neptune Wellness Solutions Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Jan 07Neptune Wellness Solutions Announces Receipt of NASDAQ NotificationNeptune Wellness Solutions Inc. announced that the Company has received a written notification (the "Notification Letter") from the Nasdaq Stock Market LLC ("Nasdaq") on December 29, 2022, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), which requires that the closing bid price for the Company's common shares listed on Nasdaq be maintained at a minimum of $1.00. Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's common shares for the 30 consecutive business days from November 15, 2022 to December 28, 2022, the Company no longer met the minimum bid price requirement. The Notification Letter has no immediate effect on the listing of the Company's common shares on Nasdaq. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until June 27, 2023, to regain compliance with the minimum bid price requirement, during which time the Company's common shares will continue to trade on the Nasdaq Capital Market. To regain compliance, the Company's common shares must have a closing bid price of at least $1.00 for a minimum of 10 consecutive trading days. In the event the Company does not regain compliance by June 27, 2023, the Company may be eligible for additional time to regain compliance or may face delisting. The Company's business operations are not affected by the receipt of the Notification Letter. The Company intends to monitor the closing bid price of its common shares and may, if appropriate, consider implementing available options, including, but not limited to, implementing a reverse share split of its outstanding common shares, to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules.
공시 • Nov 23Neptune Wellness Solutions Inc. Revises Revenue Guidance for the Second Quarter of Fiscal Year 2023Neptune Wellness Solutions Inc. revised revenue guidance for the second quarter of fiscal year 2023. For the period, the company expects revenue range from USD 12.5 million to USD 13.5 million to USD 11.5 million to USD 12.5 million. Approximately 70% of second quarter revenues were from Sprout, representing a double digit increase compared to the same quarter last year.
공시 • Nov 16+ 1 more updateNeptune Wellness Solutions Inc. announced delayed 10-Q filingOn 11/15/2022, Neptune Wellness Solutions Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Nov 10PurCann Pharma Inc. completed the acquisition of Cannabis Assets of Neptune Wellness Solutions Inc. for CAD 5.2 million.PurCann Pharma Inc. entered into a binding agreement to acquire Cannabis Assets of Neptune Wellness Solutions Inc. for approximately CAD 6 million on October 16, 2022. The cannabis assets include includes the cannabis plant in Sherbrooke, Québec, the Mood Ring and PanHash brands, and related assets. Neptune intends to use the net proceeds from the sale of these assets to for working capital and other general corporate purposes. The Transaction is expected to close on or before November 15, 2022. Stifel Nicolaus Canada Inc. acted as financial opinion provider and exclusive financial advisor to Neptune Wellness Solutions Inc. Osler, Hoskin & Harcourt LLP acted as legal advisor to Neptune Wellness Solutions Inc. PurCann Pharma Inc. completed the acquisition of Cannabis Assets of Neptune Wellness Solutions Inc. for CAD 5.2 million on November 9, 2022.
공시 • Oct 22Neptune Wellness Solutions Inc. Reaches Settlement in Shareholder Class Action LitigationNeptune Wellness Solutions Inc. announced that it has agreed to settle and resolve a putative shareholder class action lawsuit filed against Neptune and certain of its current and former officers and directors, captioned Gong v. Neptune Wellness Solutions Inc. (Case No. 2:21-cv-01386-ENV-ARL) pending in the United States District Court for the Eastern District of New York (the "Court"). The litigation relates to allegations that, among other things, the Company had made misrepresentations of material information. The settlement provides for a gross payment to the class of between $4 and $4.25 million, with the exact amount being within the Company's control and dependent on the type of consideration used. The settlement is subject to Court approval and certification by the Court of the class. The settlement will resolve this matter against all defendants, and the consideration will be used to satisfy settlement administrator expenses, plaintiffs' attorneys' fees and costs, and payments to all members of the Class. In exchange for the settlement consideration, the Company and the other defendants will be released from all claims by the plaintiffs and the class. The Company denies all wrongdoing and liability and the settlement does not constitute an admission of wrongdoing or liability by the Company or any defendant. The class is comprised of all persons and entities that purchased or otherwise acquired Neptune securities on the NASDAQ or another U.S. trading venue between July 24, 2019, and July 15, 2021. The settlement is contingent upon various conditions, including, but not limited to, preliminary approval by the Court and final approval by the Court after notice to the class, certification of the class and a hearing. There can be no assurance that the settlement will be approved by the Court nor upheld if challenged on appeal. In addition, the Company has the right to terminate the settlement agreement under certain conditions. The Company has filed a claim for coverage with its insurance carrier, which was subsequently denied. The Company is contesting the denial of coverage.
공시 • Oct 19PurCann Pharma Inc. entered into a binding agreement to acquire Cannabis Assets of Neptune Wellness Solutions Inc. for approximately CAD 6 million.PurCann Pharma Inc. entered into a binding agreement to acquire Cannabis Assets of Neptune Wellness Solutions Inc. for approximately CAD 6 million on October 16, 2022. The cannabis assets include includes the cannabis plant in Sherbrooke, Québec, the Mood Ring and PanHash brands, and related assets. Neptune intends to use the net proceeds from the sale of these assets to for working capital and other general corporate purposes. The Transaction is expected to close on or before November 15, 2022. Stifel Nicolaus Canada Inc. acted as financial opinion provider and exclusive financial advisor to Neptune Wellness Solutions Inc. Osler, Hoskin & Harcourt LLP acted as legal advisor to Neptune Wellness Solutions Inc.
공시 • Oct 13Neptune Wellness Solutions Inc. has completed a Follow-on Equity Offering in the amount of $6.000002 million.Neptune Wellness Solutions Inc. has completed a Follow-on Equity Offering in the amount of $6.000002 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 3,208,557 Price\Range: $1.87 Discount Per Security: $0.0748 Transaction Features: Registered Direct Offering
공시 • Oct 12+ 1 more updateNeptune Wellness Solutions Inc. has completed a Follow-on Equity Offering in the amount of $6.000002 million.Neptune Wellness Solutions Inc. has completed a Follow-on Equity Offering in the amount of $6.000002 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 3,208,557 Price\Range: $1.87 Discount Per Security: $0.0748 Transaction Features: Registered Direct Offering
Board Change • Jun 02High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. 6 highly experienced directors. Independent Director Ronald Denis is the most experienced director on the board, commencing their role in 2000. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Recent Insider Transactions • Mar 03President recently bought €346k worth of stockOn the 1st of March, Michael Cammarata bought around 1m shares on-market at roughly €0.31 per share. This was the largest purchase by an insider in the last 3 months. Michael has been a buyer over the last 12 months, purchasing a net total of €365k worth in shares.
Reported Earnings • Feb 11Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2022 results: CA$0.11 loss per share (up from CA$0.59 loss in 3Q 2021). Revenue: CA$18.4m (up 456% from 3Q 2021). Net loss: CA$18.7m (loss narrowed 75% from 3Q 2021). Revenue exceeded analyst estimates by 6.1%. Over the next year, revenue is forecast to grow 81%, compared to a 6.9% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has fallen by 57% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Nov 16Second quarter 2022 earnings released: CA$0.076 loss per share (vs CA$0.20 loss in 2Q 2021)The company reported a soft second quarter result with weaker revenues and control over costs, although losses reduced. Second quarter 2022 results: Revenue: CA$15.7m (down 45% from 2Q 2021). Net loss: CA$12.7m (loss narrowed 42% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 47% per year, which means it has not declined as severely as earnings.
Board Change • Sep 13High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Jane Pemberton was the last director to join the board, commencing their role in 2020. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Board Change • Sep 05High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Jane Pemberton was the last director to join the board, commencing their role in 2020. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Executive Departure • Sep 01Independent Director Jane Pemberton has left the companyOn the 26th of August, Jane Pemberton's tenure as Independent Director ended after 1.0 years in the role. As of June 2021, Jane still personally held only 9.67k shares (€9.2k worth at the time). A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 1.25 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Sep 01Independent Director Frank Rochon has left the companyOn the 26th of August, Frank Rochon's tenure as Independent Director ended after 1.0 years in the role. As of June 2021, Frank still personally held only 4.77k shares (€4.6k worth at the time). A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 1.25 years, which is considered inexperienced in the Simply Wall St Risk Model.
Recent Insider Transactions • Jul 22Independent Chairman recently bought €67k worth of stockOn the 20th of July, John Moretz bought around 100k shares on-market at roughly €0.67 per share. This was the largest purchase by an insider in the last 3 months. John has been a buyer over the last 12 months, purchasing a net total of €210k worth in shares.
Reported Earnings • Jul 18Full year 2021 earnings released: CA$1.38 loss per share (vs CA$0.68 loss in FY 2020)The company reported a mediocre full year result with increased losses and weaker control over costs, although revenues improved. Full year 2021 results: Revenue: CA$46.8m (up 58% from FY 2020). Net loss: CA$167.1m (loss widened 175% from FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 58 percentage points per year, which is a significant difference in performance.
Executive Departure • May 23Independent Director has left the companyOn the 17th of May, Richard Schottenfeld's tenure as Independent Director ended after 4.9 years in the role. As of March 2021, Richard personally held 180.45k shares (€182k worth at the time). A total of 3 executives have left over the last 12 months.
Is New 90 Day High Low • Mar 06New 90-day low: €1.15The company is down 18% from its price of €1.40 on 04 December 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is down 4.0% over the same period.
Reported Earnings • Feb 18Third quarter 2021 earnings released: CA$0.59 loss per share (vs CA$0.06 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: CA$3.32m (down 64% from 3Q 2020). Net loss: CA$73.8m (down CA$79.4m from profit in 3Q 2020).
Analyst Estimate Surprise Post Earnings • Feb 18Revenue misses expectationsRevenue missed analyst estimates by 78%. Over the next year, revenue is forecast to grow 183%, compared to a 5.4% growth forecast for the Personal Products industry in Germany.
Is New 90 Day High Low • Feb 06New 90-day high: €1.93The company is up 5.0% from its price of €1.83 on 06 November 2020. The German market is up 15% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Personal Products industry, which is down 5.0% over the same period.
Is New 90 Day High Low • Dec 15New 90-day low: €1.17The company is down 41% from its price of €1.97 on 16 September 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Recent Insider Transactions • Nov 22Independent Chairman recently bought €143k worth of stockOn the 19th of November, John Moretz bought around 100k shares on-market at roughly €1.43 per share. This was the largest purchase by an insider in the last 3 months. John has been a buyer over the last 12 months, purchasing a net total of €469k worth in shares.
